Copley Acquisition and Ignite Proteomics Strike $150M SPAC Deal to Bring Precision Oncology Proteomics Platform to Public Markets
核心洞察
Copley Acquisition Corp (搜索) and Ignite Proteomics (搜索) have entered into a definitive business combination agreement, with the combined entity expected to list on the New York Stock Exchange under Ignite Proteomics Holdings, Inc.
The transaction values the combined company at a $150 million pro forma enterprise value and is anticipated to close in the second half of 2026, subject to customary conditions.
Ignite Proteomics (搜索) specializes in pathway-level protein analytics using its Reverse Phase Protein Array platform to measure functional protein and phosphoprotein activity from tumor tissue for therapy selection.
Copley Acquisition Corp (搜索) (NYSE: COPL), a special purpose acquisition company, and Ignite Proteomics (搜索), LLC, a pioneer in pathway-level protein analytics for precision oncology, announced on June 11, 2026 that they have entered into a definitive business combination agreement. Upon closing, both companies will become wholly owned subsidiaries of a newly formed public holding company, Ignite Proteomics Holdings, Inc., which is expected to list on the New York Stock Exchange.
The proposed transaction values the combined entity at a $150 million pro forma enterprise value and is anticipated to close in the second half of 2026, subject to customary closing conditions and shareholder approvals.
A Platform Built on Direct Protein Measurement
Ignite Proteomics (搜索) has developed a proprietary Reverse Phase Protein Array platform designed to directly measure protein expression and phosphoprotein activity from tumor tissue. Unlike genomic approaches that infer protein-level changes, Ignite's technology provides functional proteomic data intended to generate therapy-selection insights across oncology.
The company's current commercial focus is in breast cancer (搜索), with a broader development strategy aimed at supporting future expansion into additional tumor types, therapeutic classes, and data-driven clinical applications.
Leadership Perspectives on the Transaction
"We are thrilled to partner with the team at Ignite Proteomics (搜索)," said Chibo Tang, Co-Chief Executive Officer of Copley Acquisition Corp (搜索). "After an extensive search for a high-impact partner, it became clear that Ignite's innovation represents a fundamental shift in how we understand and treat disease. We believe this transaction will provide Ignite with the runway and public platform required to deliver on its mission to revolutionize precision medicine."
Francis Ng, Co-Chief Executive Officer of Copley, emphasized the financial rationale behind the deal: "This transaction represents an exceptionally disciplined entry point into the precision oncology sector. At a $150 million pro forma enterprise value, we are bringing Ignite to the public markets at a highly attractive valuation. Combined with our management team's stellar capital market track records, we believe the post-closing balance sheet will be optimized to aggressively scale commercial infrastructure and capture a significant share of an addressable market expected to see impressive growth over the next decade."
Jeffrey Busch, Chief Executive Officer of Ignite Proteomics (搜索), framed the agreement as a validation of the company's scientific foundation: "Partnering with Copley marks a pivotal milestone for Ignite Proteomics. This transaction validates the technology we have spent years developing and provides the financial backing to bring our solutions to a broader market. We are eager to enter this next chapter as a public company, focused on driving long-term value for our shareholders and, most importantly, for the researchers and patients who rely on advanced proteomics."
Advisory Teams
Clear Street LLC is serving as financial advisor to Copley, with Winston Taylor LLP acting as legal counsel. Ladenburg Thalmann & Co. Inc. is serving as financial advisor to Ignite Proteomics (搜索), while Meister Seelig & Schuster PLLC is acting as legal counsel to Ignite.
Forward-Looking Considerations
The companies noted that the transaction is subject to risks and uncertainties, including the possibility that the combination may not be completed in a timely manner or at all, failure to satisfy closing conditions, and risks related to the ability of Ignite and the public holding company to execute their business plans and compete in the precision oncology industry. Additional information will be available in the registration statement on Form S-4 to be filed by Copley with the Securities and Exchange Commission.